The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 7-UK to roll out Astra/Oxford COVID vaccine after world-first approval

Wed, 30th Dec 2020 07:08

* UK ahead of others once more with emergency approval

* Britain has ordered 100 million doses of the vaccine

* Health minister eyes route out of pandemic by spring

* Regulator advocates new timing of first and second doses

* Britain to prioritise first shots over boosters
(Adds detail)

By Alistair Smout and Paul Sandle

LONDON, Dec 30 (Reuters) - Britain on Wednesday became the
first country in the world to approve the coronavirus vaccine
developed by Oxford University and AstraZeneca, hoping
that rapid action will help it stem a record surge of infections
driven by a highly contagious form of the virus.

Prime Minister Boris Johnson’s government, which has ordered
100 million doses, had already fast-tracked approval of a
vaccine developed by Pfizer of the United States and Germany's
BioNTech, and administered hundreds of thousands of shots weeks
ahead of European Union countries and the United States.

Though cheaper and easier to distribute than rival vaccines,
the Oxford/AstraZeneca shot has been plagued with questions
about its most effective dosage ever since data published last
month showed some surprising results.

While other regulators have taken a more cautious approach,
Britain's MHRA was at pains to say it had resolved early doubts
and - unexpectedly - that it had found an 80% success rate for
the administration of two full doses, three months apart, higher
than the average that the developers themselves had found.

The government plans to take advantage by giving the first
dose to a larger number of people most at risk from COVID-19
before starting to administer the boosters. An advisory body
recommended doing the same with the Pfizer shot.

Jeremy Farrar, one of Britain's leading public health
experts, said the approval was to be celebrated, but urged
continuing scrutiny, saying:

"We will ... need to continue tracking and improving our
understanding of how long the protection lasts and whether (the
vaccines) can prevent transmission. This would be best achieved
by a randomised trial on the timing of the second dose."

INFECTIONS SOAR

Britain has already registered over 70,000 deaths from
COVID-19. On Tuesday it reported a record one-day jump of 53,135
new coronavirus infections, and it fears hospitals will soon
become overstretched in their peak winter months.

The AstraZeneca/Oxford vaccine could also be a game-changer
for global immunisation. Countries with relatively basic health
infrastructure have high hopes for a shot that, unlike Pfizer's,
can be stored and transported under normal refrigeration, rather
than supercooled to -70 degrees Celsius (-94 Fahrenheit).

India's Serum Institute of India (SII), the world's biggest
producer of vaccines, has made about 50 million doses of the
Oxford vaccine, and experts at India's drug regulator were
meeting on Wednesday to consider an emergency approval, two
sources said. Chile is also interested.

World Health Organization spokesman Tarik Jasarevic said the
latest vaccine was important for its "delivery attributes, the
potential scale and affordability".

Helen Fletcher, Professor of Immunology at the London School
of Hygiene and Tropical Medicine, hailed a "turning point" for
the pandemic, which has already killed 1.7 million people around
the world, sown chaos through the global economy and upended
normal life for billions.

"With more than 30 supply agreements and partner networks
established globally, the Oxford/AstraZeneca vaccine could slow
the pandemic and should save many lives within the next year."

EU DECISION SOON?

The EU regulator says it has not yet received full data on
the AstraZeneca shot and is unlikely to be able to approve it
next month - although Germany's top vaccine official said that a
rolling review of data meant a quick decision should be
possible.

The UK's COVID-19 vaccine chair, Wei Shen Lim, said a single
dose of Oxford/AstraZeneca's vaccine was around 70% effective
from 21 days until a second dose was given at 12 weeks.

The UK Medicines and Healthcare products Regulatory Agency
(MHRA) cleared up one doubt raised by the Oxford data, saying
that a 90% success rate for a half-dose followed by a full dose
had not stood up to analysis.

However, Munir Pirmohamed, chair of a government working
group on COVID-19 vaccines and involved in the approval, said
that, when two full doses were given three months apart,
"effectiveness was high, up to 80% ... which is the reason for
our recommendation".

A Reuters investigation detailed how the apparently more
effective dosing regime was the result of a miscalculation.

AstraZeneca Chief Executive Pascal Soriot told BBC radio
that Britain should be able to vaccinate tens of millions of
people by the end of the first quarter. The firm said it
expected the vaccine to work against the new variant.

Health Secretary Matt Hancock told Sky News that he was
"highly confident that we can get enough vulnerable people
vaccinated by the spring that we can now see our route out of
this pandemic".

(Reporting by Alistair Smout and Paul Sandle in London,
additional reporting by Pushkala Aripaka in Bengaluru, Kate
Kelland in London, John Miller in Zurich, Emilio Parodi in
Milan; editing by Guy Faulconbridge and Kevin Liffey)

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.